NRBO
vs
S&P 500
NRBO
S&P 500
Over the past 12 months, NRBO has outperformed S&P 500, delivering a return of +16% compared to the S&P 500's +14% growth.
Stocks Performance
NRBO vs S&P 500
Performance Gap
NRBO vs S&P 500
Performance By Year
NRBO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neurobo Pharmaceuticals Inc
Glance View
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in the development and commercialization of therapeutics. The company is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.
